These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 28203358)

  • 21. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.
    Demin O; Yakovleva T; Kolobkov D; Demin O
    Front Pharmacol; 2014; 5():218. PubMed ID: 25352807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin Reduces Renal Hyperfiltration in Response to Uninephrectomy, but Is Not Nephroprotective in UNx/DOCA/Salt Mouse Models.
    Tauber P; Sinha F; Berger RS; Gronwald W; Dettmer K; Kuhn M; Trum M; Maier LS; Wagner S; Schweda F
    Front Pharmacol; 2021; 12():761855. PubMed ID: 34992532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM.
    Osaki A; Shimoda Y; Okada J; Yamada E; Saito T; Nakajima Y; Ozawa A; Niijima Y; Okada S; Yamada M
    Diabetes Ther; 2019 Aug; 10(4):1531-1534. PubMed ID: 31197753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
    Cariou B; Charbonnel B
    Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risks Associated with SGLT2 Inhibitors: An Overview.
    Singh M; Kumar A
    Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.
    Whaley JM; Tirmenstein M; Reilly TP; Poucher SM; Saye J; Parikh S; List JF
    Diabetes Metab Syndr Obes; 2012; 5():135-48. PubMed ID: 22923998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Packer M; Wilcox CS; Testani JM
    Circulation; 2023 Jul; 148(4):354-372. PubMed ID: 37486998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?
    Bertinat R; Nualart F; Yáñez AJ
    J Cell Physiol; 2016 Aug; 231(8):1635-7. PubMed ID: 26661279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent.
    Nomura S
    Curr Top Med Chem; 2010; 10(4):411-8. PubMed ID: 20180760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Na
    Koepsell H
    Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.
    Martens P; Mathieu C; Verbrugge FH
    Curr Treat Options Cardiovasc Med; 2017 Mar; 19(3):23. PubMed ID: 28299616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
    Washburn WN; Poucher SM
    Expert Opin Investig Drugs; 2013 Apr; 22(4):463-86. PubMed ID: 23452053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.